Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenpipramide SCHEMBL149504 | 1.00 | CHRM2 (0.60) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| Fenpipramide SCHEMBL7558279 | 0.98 | CHRM2 (0.59) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| Fenpipramide SCHEMBL11716116 | 0.96 | OPRM1 (0.56) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| Norpipanone SCHEMBL25085 | 0.87 | OPRM1 (0.75) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| Norpipanone SCHEMBL316886 | 0.85 | OPRM1 (0.73) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| SCHEMBL8880422 | 0.84 | CHRM2 (0.47) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| SCHEMBL9248078 | 0.84 | KMT2A (0.57) | OPRM1HTR1ALMNAOPRD1SIGMAR1 | |
| SCHEMBL11722508 | 0.82 | CYP2D6 (0.57) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| SCHEMBL10768406 | 0.81 | OPRM1 (0.63) | CHRM2CYP2D6CHRM1OPRM1KCNH2 | |
| SCHEMBL1492481 | 0.81 | OPRM1 (0.63) | CHRM2CYP2D6CHRM1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | claimed |
| EP-2114972-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | Gilead Sciences, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008076269-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-4764604-A | Derivatives of gamma-cyclodextrin | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-16 | — | — | US | disclosed |
| EP-0227173-A2 | New method for the detection of specific binding agents and their corresponding bindable substances | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-07-01 | — | — | EP | disclosed |
| EP-0197571-A2 | Novel derivatives of gamma-cyclodextrin | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | CHRM2 1957/4885CYP2D6 160/4885CHRM1 887/4885 |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | CHRM2 4475/4885CYP2D6 217/4885CHRM1 4534/4885 |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | ADRB1, ADRB2, CHRM3 | CHRM2 5/4885CYP2D6 883/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.